Menten AI uses physics-based generative AI to design peptide macrocycles for drug discovery, accelerating the creation of new medicines.
Menten AI develops a physics-based generative AI platform, MAUD 1.0, specifically for the de novo design of peptide macrocycles. This platform aims to unlock the potential of peptides for creating life-changing medicines, particularly for complex drug targets like Protein-Protein Interfaces. MAUD 1.0 integrates generative AI with physics-based models and quantum simulations to design and optimize drug-like peptides. This approach differs from traditional screening methods by accelerating discovery and expanding the accessible chemical space for drug development. The platform has demonstrated capabilities in achieving nM-level potency, oral bioavailability, cell-permeability, and a high hit rate (>90%). Menten AI partners with top pharmaceutical companies and is backed by leading venture capitalists, validating its technology across the preclinical discovery pipeline.
Platforms: Web
View full Menten AI profile on Tools-Radar | Browse Research tools | Alternatives to Menten AI
Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com